Related Experiment Video
Updated: Mar 27, 2026
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
NCI-60 Cell Line Screening: A Radical Departure in its Time
1Massachusetts General Hospital Cancer Center, Boston, MA. bchabner@partners.org.
Abstract:
The year 2015 marked the 30th anniversary of National Cancer Institute's (NCI's) initial effort to establish a human cell line panel as the basis for discovering new cancer drugs. At its inception, the NCI-60 panel was a controversial departure, born of frustration with previous efforts that employed murine tumors and grounded in the hope that the biology of human tumors was diverse and somehow quite different than the murine leukemia used for the previous 30 years. And while the NCI-60 has not revolutionized cancer drug discovery in terms of the new drugs that resulted, it represents a turning point in the philosophy and practice of cancer drug research.
Insights
The National Cancer Institute (NCI) established the NCI-60 human cell line panel 30 years ago. This cancer research tool shifted drug discovery philosophy despite not revolutionizing new drug development.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- The National Cancer Institute (NCI) initiated a human cell line panel for cancer drug discovery in 2015, marking 30 years of effort.
- The NCI-60 panel was a significant departure from previous methods using murine tumors, aiming to capture human tumor diversity.
More Related Videos
09:44High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
Published on: March 3, 2015
12:32Chromosome Screening of Human Preimplantation Embryos by Using Spent Culture Medium: Sample Collection and Chromosomal Ploidy Analysis
Published on: September 7, 2021
